For breast cancer survivors — particularly those with hormone receptor-positive disease — the non-hormonal management of menopause symptoms is not a fallback option; it is often the only option. Yet the evidence base for non-hormonal interventions in this population is uneven, frequently misrepresented, and rapidly evolving. In this session, Dr. Milana Dolezal delivers a rigorous, data-driven review of the current non-hormonal landscape for vasomotor and genitourinary symptoms in breast cancer survivors: what the clinical trial evidence actually supports for pharmacologic agents including SSRIs, SNRIs, gabapentinoids, and NK3 receptor antagonists; the evidence on non-pharmacologic approaches; and the critical oncologic safety considerations that must frame all treatment decisions in this population. A session built for the clinician who needs the evidence — not the marketing.

Milana V. Dolezal, MD, MSci, is a board-certified hematologist-oncologist and Clinical Associate Professor in the Division of Oncology at Stanford School of Medicine, where she practices at Stanford Medicine Cancer Center in Emeryville. Her clinical and research work centers on breast cancer, with particular expertise in triple-negative breast cancer, fertility preservation in breast cancer patients, and treatment adherence. She previously served as Clinical Scientist and Associate Medical Director in the BioOncology Therapeutics unit at Genentech, bringing rare depth in both translational science and drug development to her academic oncology practice. Dr. Dolezal has co-authored peer-reviewed research published in the Journal of Clinical Oncology, Cancer, and other leading journals, and contributed the chapter "Progression from Hormone-Dependent to Hormone-Independent Breast Cancer" to the Oxford University Press textbook Hormones, Genes and Cancer. She has presented her research at the American Association for Cancer Research, the American Society of Clinical Oncology, and the European Cancer Organisation.